Condition
Mesothelioma
Estimated Enrollment: 37
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 03-369
Study First Received: August 29, 2005
Last Updated: December 23, 2011
Estimated Primary Completion Date: March 2007
Primary Outcome Measures:
To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma|To determine the time to tumor progression|to determine the duration of response|to determine the median and overall survival of patients|to determine the safety of the drugs administered
Sponsors and Collaborators:
Dana-Farber Cancer Institute|Massachusetts General Hospital|University of Chicago
Website Link: https://ClinicalTrials.gov/show/NCT00137826
